pteridines has been researched along with Sarcoma in 2 studies
Sarcoma: A connective tissue neoplasm formed by proliferation of mesodermal cells; it is usually highly malignant.
| Excerpt | Relevance | Reference |
|---|---|---|
| "BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1." | 6.75 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010) |
| "BI 2536 is a selective and potent small-molecule inhibitor of polo-like kinase 1." | 2.75 | Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research ( Aerts, C; Allgeier, A; Blay, JY; Bogaerts, J; Brain, E; De Greve, J; Fontaine, C; Fritsch, H; Hanft, G; Lacombe, D; Machiels, JP; Munzert, G; Rapion, J; Ray-Coquard, I; Schöffski, P; Sleijfer, S; Soria, JC; Wolter, P, 2010) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (50.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Schöffski, P | 1 |
| Blay, JY | 1 |
| De Greve, J | 1 |
| Brain, E | 1 |
| Machiels, JP | 1 |
| Soria, JC | 1 |
| Sleijfer, S | 1 |
| Wolter, P | 1 |
| Ray-Coquard, I | 1 |
| Fontaine, C | 1 |
| Munzert, G | 1 |
| Fritsch, H | 1 |
| Hanft, G | 1 |
| Aerts, C | 1 |
| Rapion, J | 1 |
| Allgeier, A | 1 |
| Bogaerts, J | 1 |
| Lacombe, D | 1 |
| Katoh, S | 1 |
| Sueoka, T | 1 |
| Hirayama, K | 1 |
| Masuda, I | 1 |
| Nakanishi, N | 1 |
| Yamada, S | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Multicenter Parallel Phase II Trial of BI 2536 Administered as One Hour IV Infusion Every 3 Weeks in Defined Cohorts of Patients With Various Solid Tumors. A New Drug Screening Program of the EORTC Network of Core Institutions (NOCI)[NCT00526149] | Phase 2 | 76 participants (Actual) | Interventional | 2007-07-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for pteridines and Sarcoma
| Article | Year |
|---|---|
Multicentric parallel phase II trial of the polo-like kinase 1 inhibitor BI 2536 in patients with advanced head and neck cancer, breast cancer, ovarian cancer, soft tissue sarcoma and melanoma. The first protocol of the European Organization for Research
Topics: Adult; Aged; Antineoplastic Agents; Breast Neoplasms; Feasibility Studies; Female; Head and Neck Neo | 2010 |
1 other study available for pteridines and Sarcoma
| Article | Year |
|---|---|
[Phenylalanine hydroxylating activity in Tawa sarcoma].
Topics: Animals; Biopterins; Hydroxylation; Liver Neoplasms; Neoplasms, Experimental; Phenylalanine Hydroxyl | 1981 |